Susquehanna International Group, LLP Bei Gene, Ltd. Transaction History

Susquehanna International Group, LLP

$560 Billion
Q3 2024

A detailed history of Susquehanna International Group, LLP transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 3,042 shares of BGNE stock, worth $544,700. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,042

Previous 11,094 72.58%

Holding current value

$544,700

Previous $1.58 Million 56.89%

% of portfolio

0.0%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$143.93 - $224.51 $1.16 Million - $1.81 Million	-8,052 Reduced 72.58%	3,042 $682,000
Q2 2024 Aug 15, 2024	BUY	$129.52 - $174.32 $1.44 Million - $1.93 Million	11,094 New	11,094 $1.58 Million
Q3 2023 Nov 14, 2023	SELL	$179.87 - $225.13 $2.1 Million - $2.63 Million	-11,663 Reduced 59.77%	7,849 $1.41 Million
Q2 2023 Aug 11, 2023	BUY	$178.3 - $266.78 $3.48 Million - $5.21 Million	19,512 New	19,512 $3.48 Million
Q4 2022 Feb 14, 2023	BUY	$125.51 - $229.3 $791,340 - $1.45 Million	6,305 Added 295.18%	8,441 $1.86 Million
Q3 2022 Nov 14, 2022	BUY	$131.8 - $202.24 $281,524 - $431,984	2,136 New	2,136 $288,000
Q1 2022 May 16, 2022	SELL	$146.52 - $269.56 $25,494 - $46,903	-174 Reduced 11.37%	1,356 $256,000
Q4 2021 Feb 14, 2022	BUY	$248.56 - $389.34 $193,876 - $303,685	780 Added 104.0%	1,530 $415,000
Q3 2021 Nov 15, 2021	SELL	$249.6 - $403.14 $629,990 - $1.02 Million	-2,524 Reduced 77.09%	750 $272,000
Q2 2021 Aug 11, 2021	BUY	$292.75 - $367.01 $787,790 - $987,623	2,691 Added 461.58%	3,274 $1.12 Million
Q1 2021 May 17, 2021	SELL	$260.64 - $382.12 $1.28 Million - $1.87 Million	-4,895 Reduced 89.36%	583 $203,000
Q4 2020 Feb 16, 2021	SELL	$221.31 - $316.61 $509,455 - $728,836	-2,302 Reduced 29.59%	5,478 $1.42 Million
Q3 2020 Nov 16, 2020	BUY	$189.18 - $286.44 $856,985 - $1.3 Million	4,530 Added 139.38%	7,780 $2.23 Million
Q2 2020 Aug 14, 2020	SELL	$123.9 - $195.41 $5.71 Million - $9 Million	-46,068 Reduced 93.41%	3,250 $612,000
Q1 2020 May 15, 2020	BUY	$121.84 - $173.19 $4.38 Million - $6.22 Million	35,939 Added 268.62%	49,318 $6.07 Million
Q4 2019 Feb 14, 2020	SELL	$115.78 - $208.34 $1 Million - $1.8 Million	-8,640 Reduced 39.24%	13,379 $2.22 Million
Q3 2019 Nov 14, 2019	BUY	$120.61 - $148.29 $1.29 Million - $1.59 Million	10,695 Added 94.45%	22,019 $2.7 Million
Q2 2019 Aug 16, 2019	SELL	$113.99 - $146.86 $1.51 Million - $1.95 Million	-13,245 Reduced 53.91%	11,324 $1.4 Million
Q2 2018 Aug 14, 2018	BUY	$152.5 - $216.77 $156,007 - $221,755	1,023 Added 4.34%	24,569 $3.78 Million
Q4 2017 Feb 14, 2018	BUY	$79.6 - $114.73 $1.87 Million - $2.7 Million	23,546	23,546 $2.3 Million

Others Institutions Holding BGNE

# of Institutions

252

Shares Held

45.3M

Call Options Held

292K

Put Options Held

119K

View Full List

About BeiGene, Ltd.

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $18.6B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

More about BGNE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account

Susquehanna International Group, LLP Bei Gene, Ltd. Transaction History